Aardvark Therapeutics will debut on Nasdaq at $16/share, to raise $94M for hunger-focused metabolic disease treatments. ARD-101 Phase 3 data expected early 2025.

Hexaware IPO opens for subscription on February 12, with a price band of ₹674 to ₹708 per share. The offering is entirely an ...

The U.S. IPO market is gaining momentum, with several issuers set for this week. Notably, defense contractor Karman Space & ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...